Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.   The production agreement is part of AstraZeneca’s recently announced in-licensed program with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at n...